
CSL says the most ambitious clinical trial in its 107-year history has failed to show any benefit to a highly touted potential treatment aimed at stopping secondary heart attacks.
CSL has spent two decades and nearly $1 billion developing CSL112, a treatment derived from human blood plasma.